{"meta":{"query_hash":"f45526ca5810","filters":{"venue":"ESMO rare cancers."},"cohort_total":18,"direct_labels_cover":0,"predictions_cover":18,"exported":18,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/f45526ca5810","api":"https://metacan.xera.ac/api/v1/cohort?venue=ESMO+rare+cancers."},"results":[{"id":"W4417530834","doi":"10.1016/j.esmorc.2025.100073","title":"RADIOLOGIC RESPONSES IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Dermatological and Skeletal Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Feature (linguistics); Medical imaging; Disease; MEDLINE; Computed tomography","score_opus":0.006966873779264059,"score_gpt":0.2581287047792288,"score_spread":0.2511618309999647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92068017,0.048335038,0.0058282046,0.0074515366,0.00022084785,0.00022432143,0.0015918888,0.00024966462,0.015418349],"genre_scores_gemma":[0.98889786,0.0044966377,0.0025067069,0.0016418375,0.00031926515,0.00006988234,0.0009867079,0.000042514275,0.001038533],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975993,0.0010201706,0.00036733918,0.00027315598,0.0005404714,0.00019946665],"domain_scores_gemma":[0.99510276,0.0019118856,0.001589353,0.0002605241,0.00087070174,0.0002647136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042465827,0.0002416179,0.00091182976,0.00070829614,0.00019534139,0.0007368329,0.00049374945,0.00041667416,0.0013723283],"category_scores_gemma":[0.0073541137,0.000078275145,0.00037354857,0.0010123001,0.0003421132,0.0008793196,0.00037127145,0.00071132527,0.00053348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042930692,0.00020594607,0.52788186,0.0012434473,0.0004561429,0.0033509855,0.00057875516,0.0020669883,0.009727767,0.00055875327,0.010707929,0.4389284],"study_design_scores_gemma":[0.0003194002,0.0030429678,0.884541,0.00095218845,0.0007729489,0.0274452,0.0013163936,0.005573603,0.01542474,0.0022963753,0.058256287,0.000058852078],"about_ca_topic_score_codex":0.0006387862,"about_ca_topic_score_gemma":0.0016502315,"teacher_disagreement_score":0.0042465827,"about_ca_system_score_codex":0.0006831663,"about_ca_system_score_gemma":0.00026453,"threshold_uncertainty_score":0.022458315},"labels":[],"label_agreement":null},{"id":"W4417530841","doi":"10.1016/j.esmorc.2025.100102","title":"NRG-DT001 PHASE IB TRIAL OF NEOADJUVANT NAVTEMADLIN AND RADIOTHERAPY IN TP53 WILD-TYPE SOFT TISSUE SARCOMA: PRELIMINARY EFFICACY ANALYSIS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Soft tissue sarcoma; Radiation therapy; Tolerability; Soft tissue; Sarcoma; Clinical trial; Phases of clinical research","score_opus":0.01758124853013332,"score_gpt":0.3460718606338129,"score_spread":0.3284906121036796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826583,0.0059346594,0.00064132625,0.0010230192,0.00031357046,0.001146805,0.0022840702,0.0001641054,0.005834176],"genre_scores_gemma":[0.9771409,0.00649865,0.002432858,0.0010870484,0.00021688016,0.001471791,0.0052925413,0.00005784163,0.005801463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99962115,0.00019458566,0.000023659852,0.000051585594,0.000040122177,0.000068812646],"domain_scores_gemma":[0.99948645,0.00013107288,0.00008750326,0.00005185385,0.000023921739,0.00021921037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014812689,0.001123046,0.0014387675,0.00036541212,0.00022868629,0.0009748028,0.0006890039,0.000711746,0.0043472005],"category_scores_gemma":[0.0009054595,0.00035419702,0.0012246835,0.00042374662,0.0008838779,0.0009253302,0.0002789047,0.0023209795,0.00093136565],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67640036,0.026754554,0.0056484076,0.0014943166,0.0020950367,0.00029064144,0.00026386417,0.005833121,0.037075605,0.0012661942,0.009482565,0.23339532],"study_design_scores_gemma":[0.47501814,0.48184565,0.019945512,0.00027368005,0.0014105501,0.0007718861,0.00020064093,0.0038591048,0.0053363224,0.00091184775,0.01035469,0.000071911956],"about_ca_topic_score_codex":0.0015406073,"about_ca_topic_score_gemma":0.007311065,"teacher_disagreement_score":0.0043472005,"about_ca_system_score_codex":0.0010983093,"about_ca_system_score_gemma":0.0016798178,"threshold_uncertainty_score":0.014542878},"labels":[],"label_agreement":null},{"id":"W4417530842","doi":"10.1016/j.esmorc.2025.100077","title":"MANAGEMENT OF THE DUODENUM DURING RESECTION OF PRIMARY RETROPERITONEAL SARCOMA: SURGICAL AND ONCOLOGICAL OUTCOMES FROM A MULTICENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Duodenum; Multicenter study; Resection; Surgical resection; Segmental resection","score_opus":0.020621312955444945,"score_gpt":0.296546458373951,"score_spread":0.27592514541850605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996793,0.0001034401,0.000029328492,0.000013104698,0.0000016232414,0.0000059132376,0.000087099565,8.705339e-7,0.00007929008],"genre_scores_gemma":[0.99964213,0.000057530768,0.000043793407,0.000014409615,0.000008012606,0.0000057186776,0.00020342579,8.940007e-7,0.000024092564],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929404,0.00027898874,0.00009373631,0.00015022422,0.00010525979,0.00007762117],"domain_scores_gemma":[0.99733824,0.00031141008,0.0015931603,0.00019879524,0.00020804831,0.0003502933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013313473,0.00028548716,0.00027657714,0.0005192618,0.0003445653,0.00065100915,0.00035783643,0.00033323368,0.0009155174],"category_scores_gemma":[0.002524542,0.00020830135,0.00049887266,0.00074713957,0.00028115296,0.0004862883,0.0007045436,0.00034143205,0.00020819453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021272326,0.00004972295,0.9985299,0.000008799065,0.000060079565,0.0000979633,0.00007796845,0.0000206234,0.0001395418,0.000004369487,0.000037645234,0.00076071033],"study_design_scores_gemma":[0.00003704023,0.0003756516,0.9979304,0.000009858313,0.00006222523,0.0008621879,0.0003378655,0.00011059425,0.0000895722,0.000007840149,0.00017244957,0.00000429908],"about_ca_topic_score_codex":0.001484868,"about_ca_topic_score_gemma":0.0020101815,"teacher_disagreement_score":0.001484868,"about_ca_system_score_codex":0.00035557285,"about_ca_system_score_gemma":0.00034266876,"threshold_uncertainty_score":0.007040918},"labels":[],"label_agreement":null},{"id":"W4417530843","doi":"10.1016/j.esmorc.2025.100061","title":"JAK/STAT PATHWAY CO-OPERATES WITH CIC-FUSIONS TO DRIVE CIC-REARRANGED SARCOMAS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University Health Network; Barrie Urology Group","funders":"","keywords":"Sarcoma; Mutation; Cancer; Cell culture","score_opus":0.017030919063464094,"score_gpt":0.3220248881436876,"score_spread":0.3049939690802235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97523075,0.001404563,0.0060372907,0.00077307236,0.00022375278,0.00011049714,0.0017396536,0.0007422252,0.01373811],"genre_scores_gemma":[0.993222,0.00026289024,0.0011540594,0.00012228481,0.000010518075,0.000024738763,0.0006684204,0.000052683197,0.0044824625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996457,0.000034072193,0.00003060895,0.0000649734,0.00013026375,0.00009440889],"domain_scores_gemma":[0.9997423,0.0000640867,0.000057855337,0.000051235973,0.000018452267,0.000066097644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002487665,0.00028580907,0.00018184517,0.0004953471,0.00035499246,0.0008030718,0.00025880415,0.0006063172,0.0064874147],"category_scores_gemma":[0.0003858875,0.00023619006,0.00029925408,0.00030351142,0.00045251125,0.00026825434,0.00059767364,0.0013246881,0.0023790142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009551324,0.000060729977,0.0015422842,0.00005398861,0.000018079729,0.0010738837,0.000050281567,0.00036598608,0.98979,0.0019449409,0.0011179678,0.0038864],"study_design_scores_gemma":[0.000066030385,0.00019767082,0.014984776,0.00002624224,0.00004081853,0.007868342,0.00016135685,0.0056189727,0.94194955,0.00071505754,0.02835297,0.00001817766],"about_ca_topic_score_codex":0.0008678036,"about_ca_topic_score_gemma":0.0017262084,"teacher_disagreement_score":0.0064874147,"about_ca_system_score_codex":0.0006313277,"about_ca_system_score_gemma":0.00042718078,"threshold_uncertainty_score":0.021702588},"labels":[],"label_agreement":null},{"id":"W4417530849","doi":"10.1016/j.esmorc.2025.100092","title":"INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA, A PUSH PLATFORM STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Anschutz Medical Campus, University of Colorado; Università degli Studi di Torino; Albert-Ludwigs-Universität Freiburg; Justus Liebig Universität Gießen; University of Texas MD Anderson Cancer Center; St. Jude Children's Research Hospital; Universitätsklinikum Hamburg-Eppendorf; School of Medicine, Duke University; Ohio State University; University of Pennsylvania; Children's Hospital of Philadelphia; Nationwide Children's Hospital; Massachusetts Institute of Technology","keywords":"Retrospective cohort study; Multicenter study; MEDLINE; Real world data","score_opus":0.02273181365827817,"score_gpt":0.30612275018123375,"score_spread":0.28339093652295555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783903,0.00041617022,0.00009865814,0.000025034507,0.0000048902916,0.000032062737,0.00061613345,0.0000034188547,0.00096465653],"genre_scores_gemma":[0.99802256,0.00023855388,0.00010233046,0.000056145986,0.000024369185,0.000044040797,0.0013121353,0.0000065268487,0.00019337834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994344,0.00011775854,0.00006643245,0.00018619165,0.00007415614,0.00012103585],"domain_scores_gemma":[0.9991823,0.00009283587,0.00027484834,0.00014538983,0.00009626183,0.00020847812],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008717635,0.0006724041,0.0004900236,0.0010075484,0.0006347842,0.0009772386,0.00038901766,0.00039886674,0.0021962894],"category_scores_gemma":[0.0012081664,0.0005351303,0.0005506554,0.0018944632,0.00041374777,0.00079337024,0.00080055493,0.0005134947,0.0005222925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012032845,0.00011071727,0.99454886,0.000041778745,0.00026224516,0.0003883917,0.00018051283,0.000057020694,0.00070441485,0.00010904454,0.00039656358,0.0019970043],"study_design_scores_gemma":[0.00020820792,0.00051605946,0.99475646,0.00003243835,0.00056998286,0.0011653616,0.00089269393,0.00017424583,0.00022746192,0.00008017453,0.0013589311,0.000017947264],"about_ca_topic_score_codex":0.0027788484,"about_ca_topic_score_gemma":0.0038427466,"teacher_disagreement_score":0.0027788484,"about_ca_system_score_codex":0.00037395261,"about_ca_system_score_gemma":0.00065285823,"threshold_uncertainty_score":0.0073472857},"labels":[],"label_agreement":null},{"id":"W4417530851","doi":"10.1016/j.esmorc.2025.100096","title":"DATA DRIVEN MODELLING OF SPATIAL HETEROGENEITY IN SOFT TISSUE SARCOMAS IDENTIFIES PROGNOSTIC GROUPS FOLLOWING NEOADJUVANT CHEMOTHERAPY: ANALYSIS OF THE ISG-STS-1001 TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Soft tissue; Radiation therapy; Neoadjuvant therapy; Data-driven; Tumour heterogeneity; Sarcoma; Spatial heterogeneity","score_opus":0.02480526418381184,"score_gpt":0.29160813987829093,"score_spread":0.2668028756944791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819874,0.0015504139,0.0065172883,0.0021718638,0.00010096682,0.00017062956,0.006050373,0.00013281041,0.0013180692],"genre_scores_gemma":[0.99211407,0.00021036166,0.0019757815,0.00021770138,0.00004310473,0.0001806757,0.004267151,0.000039206116,0.0009519299],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99662834,0.0027755916,0.00008587556,0.0002627847,0.00010244609,0.00014496097],"domain_scores_gemma":[0.97807753,0.018566845,0.0013184339,0.0011903796,0.0003643522,0.00048243217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013618088,0.0010204546,0.0021250814,0.00036821823,0.0002041609,0.0012239908,0.0016495875,0.001231621,0.002572134],"category_scores_gemma":[0.020048415,0.000550767,0.0025639932,0.00061080244,0.0006009223,0.0006524508,0.00085214025,0.0017484981,0.0004343418],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044944093,0.0009850484,0.067400314,0.0006043208,0.0038277882,0.00027580885,0.00015344722,0.8381316,0.0011691153,0.0033003814,0.009643781,0.029564219],"study_design_scores_gemma":[0.005128821,0.0031736668,0.025008192,0.000072548406,0.0014775392,0.00014107034,0.00009173618,0.954936,0.0009538068,0.0061612534,0.002786652,0.00006855715],"about_ca_topic_score_codex":0.0059742588,"about_ca_topic_score_gemma":0.004829119,"teacher_disagreement_score":0.013618088,"about_ca_system_score_codex":0.0010360838,"about_ca_system_score_gemma":0.0012003805,"threshold_uncertainty_score":0.07202017},"labels":[],"label_agreement":null},{"id":"W4417530860","doi":"10.1016/j.esmorc.2025.100076","title":"GENOME-WIDE SEQUENCING ANALYSES REVEAL THE BIOLOGICAL DETERMINANTS OF RESECTION MARGIN STATUS IN PRIMARY RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Hospital for Sick Children; Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Liposarcoma; Resection margin; Resection; Margin (machine learning); Surgical margin; Radiation therapy","score_opus":0.05800347749770376,"score_gpt":0.33361318267646034,"score_spread":0.2756097051787566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99873406,0.00021895366,0.00023351038,0.000021688635,0.0000013285658,0.0000074782197,0.0005852367,0.000006969191,0.00019077],"genre_scores_gemma":[0.99895835,0.000058126625,0.00024300591,0.000020099484,0.0000015182446,0.0000060580137,0.00060072966,0.0000022047582,0.000109940534],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985445,0.000024053115,0.000014421214,0.000049642542,0.000033865508,0.000023565672],"domain_scores_gemma":[0.9997881,0.00007349601,0.000087903754,0.000011530232,0.000014553675,0.00002433559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028366558,0.0001323931,0.00015553294,0.00029919244,0.00011202752,0.00022215015,0.00011895947,0.00018548786,0.0014730154],"category_scores_gemma":[0.00047847375,0.0000960131,0.00015236755,0.00028106317,0.000112729096,0.00009135146,0.00018267012,0.00017397873,0.00016855757],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041695954,0.00022258742,0.6872775,0.00017905675,0.00038432563,0.0017407414,0.00017980214,0.0013952324,0.26618508,0.00018689976,0.00062803994,0.037451096],"study_design_scores_gemma":[0.000091654765,0.00041226103,0.98288757,0.000016345593,0.00014484965,0.0022407682,0.00009570892,0.0011323408,0.011709717,0.0001338205,0.0011288688,0.000006056216],"about_ca_topic_score_codex":0.0003103959,"about_ca_topic_score_gemma":0.0008913883,"teacher_disagreement_score":0.0014730154,"about_ca_system_score_codex":0.000120005716,"about_ca_system_score_gemma":0.00009426591,"threshold_uncertainty_score":0.004927695},"labels":[],"label_agreement":null},{"id":"W4417530862","doi":"10.1016/j.esmorc.2025.100084","title":"PREDICTING FAILURE OF ACTIVE SURVEILLANCE IN DESMOID-TYPE FIBROMATOSIS USING RADIOMICS: AN INTERNATIONAL MULTI-CENTER STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Princess Margaret Cancer Centre; Sinai Health System","funders":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Thomas Jefferson University; University of Miami","keywords":"Radiomics; Fibromatosis; Medical imaging; MEDLINE; Personalized medicine","score_opus":0.032320563403784405,"score_gpt":0.3448138099901654,"score_spread":0.312493246586381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990903,0.00030711107,0.00007043105,0.000024769291,0.0000042111064,0.000010109803,0.000067053865,0.000001485915,0.00042459002],"genre_scores_gemma":[0.9996061,0.00012423555,0.00007492002,0.000015234081,0.000013322956,0.0000047530475,0.00011653055,0.0000011169215,0.000043755837],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9994814,0.00019438172,0.000061547835,0.0001041743,0.00006813094,0.00009036512],"domain_scores_gemma":[0.9981212,0.00059569755,0.0006313145,0.00014918779,0.00021239868,0.00029021877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013503837,0.0003921952,0.00035480468,0.001346345,0.00038154624,0.000882881,0.00040148234,0.0006097026,0.0010434034],"category_scores_gemma":[0.0031651123,0.00023507215,0.00049171085,0.000863619,0.00042395122,0.0007675593,0.00047344435,0.00051997975,0.00017570134],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012403738,0.000052566487,0.9981725,0.000005636735,0.000036587317,0.00017205472,0.000081754624,0.000029751802,0.0001638312,0.000012077627,0.000035639194,0.0011134052],"study_design_scores_gemma":[0.0000145597605,0.0003066295,0.996838,0.000013024925,0.00011944988,0.0013369902,0.0005745127,0.00037173624,0.00011973135,0.000025977099,0.0002719596,0.0000074192058],"about_ca_topic_score_codex":0.0017795728,"about_ca_topic_score_gemma":0.0019111462,"teacher_disagreement_score":0.0017795728,"about_ca_system_score_codex":0.00026051037,"about_ca_system_score_gemma":0.00024069818,"threshold_uncertainty_score":0.00714159},"labels":[],"label_agreement":null},{"id":"W4417530877","doi":"10.1016/j.esmorc.2025.100056","title":"INTEGRATED EFFICACY AND SAFETY ANALYSIS OF LETETRESGENE AUTOLEUCEL, A T-CELL RECEPTOR T-CELL THERAPY, ACROSS CLINICAL TRIALS OF PATIENTS WITH SYNOVIAL SARCOMA AND MYXOID/ROUND CELL LIPOSARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Soft tissue sarcoma; Synovial sarcoma; Liposarcoma; Sarcoma; Receptor","score_opus":0.03792771047108455,"score_gpt":0.35563736217022296,"score_spread":0.3177096516991384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971603,0.001667603,0.00036290463,0.00003631676,0.000012179901,0.00014974058,0.00027134485,0.000013512455,0.00032602865],"genre_scores_gemma":[0.99801826,0.00042729115,0.00029527943,0.00006362256,0.000018860263,0.00016209368,0.0007307794,0.0000057071993,0.00027802683],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9991881,0.0004043521,0.00007136775,0.00013599805,0.00012395454,0.00007619893],"domain_scores_gemma":[0.9993919,0.0001534977,0.00021765984,0.00006497264,0.00006224722,0.000109696615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024182873,0.00046793808,0.0011079906,0.00045406868,0.00014826127,0.0006154129,0.00025743854,0.0003317236,0.00071784813],"category_scores_gemma":[0.00090750254,0.00019442919,0.00070676854,0.00036589633,0.00033900255,0.00045819036,0.00027867613,0.0005493129,0.00014911065],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36944515,0.011592429,0.18818785,0.0014064695,0.008963272,0.00029434526,0.0005341557,0.0074403835,0.17811546,0.0003605245,0.0014185791,0.2322414],"study_design_scores_gemma":[0.032497574,0.48841205,0.43736985,0.00007774402,0.00592224,0.0007660835,0.00031153116,0.004327398,0.023621626,0.0003089786,0.0063303174,0.000054512177],"about_ca_topic_score_codex":0.0001843497,"about_ca_topic_score_gemma":0.0006646984,"teacher_disagreement_score":0.0024182873,"about_ca_system_score_codex":0.00048800642,"about_ca_system_score_gemma":0.00040435194,"threshold_uncertainty_score":0.012789309},"labels":[],"label_agreement":null},{"id":"W4417530885","doi":"10.1016/j.esmorc.2025.100072","title":"OVERCOMING MTOR INHIBITOR RESISTANCE IN PECOMA: UPDATED RESULTS ON AROMATASE INHIBITOR ADDITION FROM A REFERRAL CENTER","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Nitric Oxide and Endothelin Effects","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Discovery and development of mTOR inhibitors; Aromatase inhibitor; Aromatase; Clinical trial; PI3K/AKT/mTOR pathway; Referral","score_opus":0.01383670230329569,"score_gpt":0.2705782362036146,"score_spread":0.2567415339003189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745482,0.014655198,0.0009852353,0.00043644317,0.00005658127,0.00010446145,0.004569994,0.000079855185,0.004563892],"genre_scores_gemma":[0.98170257,0.008772227,0.0011893947,0.00058265845,0.0001952713,0.000051843053,0.0067629055,0.00003386376,0.0007092559],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980108,0.00046823907,0.00039530476,0.0004066675,0.00054450653,0.00017440126],"domain_scores_gemma":[0.9929783,0.0019900703,0.002527104,0.0004438178,0.0016624393,0.00039829104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014979395,0.00032265423,0.0006277562,0.0013276866,0.00021033846,0.0008466565,0.0003841644,0.00034531477,0.0019065102],"category_scores_gemma":[0.0049364464,0.00017447877,0.00066956837,0.0022502097,0.00015729477,0.0005694689,0.0004654965,0.0004625205,0.0005812548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022064277,0.00027790538,0.7952058,0.00069708435,0.0005434907,0.0014544303,0.0005495785,0.0006233981,0.0048497263,0.00005131355,0.0033961518,0.19014488],"study_design_scores_gemma":[0.00012689455,0.0013531159,0.97834593,0.00019128098,0.00074051146,0.004244072,0.00031198573,0.00034537492,0.0027666513,0.000018719482,0.011524647,0.000030810566],"about_ca_topic_score_codex":0.003127883,"about_ca_topic_score_gemma":0.003781525,"teacher_disagreement_score":0.003127883,"about_ca_system_score_codex":0.00057998725,"about_ca_system_score_gemma":0.00064880843,"threshold_uncertainty_score":0.007921934},"labels":[],"label_agreement":null},{"id":"W4417530891","doi":"10.1016/j.esmorc.2025.100116","title":"THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; European Network for Rare Adult Solid Cancers; Feinberg School of Medicine; Centre Léon Bérard; Universitair Medisch Centrum Groningen; Cleveland Clinic; University College London; Institut Gustave-Roussy; Vanderbilt University; Moffitt Cancer Center; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, San Francisco; Vanderbilt University Medical Center; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Johns Hopkins University; University of Texas MD Anderson Cancer Center; Northwestern University; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Agonist; Placebo; Clinical trial; Receptor; Phase (matter)","score_opus":0.023166413158263975,"score_gpt":0.3242507285497494,"score_spread":0.30108431539148545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849835,0.010308917,0.0004569522,0.0004654851,0.0001820182,0.00065703073,0.000787611,0.00008863509,0.0020698803],"genre_scores_gemma":[0.98835796,0.0061058896,0.0006348179,0.00065549475,0.00013700988,0.00055023696,0.0014261598,0.000024115301,0.0021084382],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99965703,0.00018024241,0.000021153804,0.00003576924,0.000045593628,0.0000600924],"domain_scores_gemma":[0.9997003,0.0000711126,0.00010006597,0.000032015476,0.000025099964,0.00007136873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095649756,0.00077044184,0.0012085376,0.00023168133,0.00018942766,0.00062725623,0.00054969604,0.0007295541,0.0025118315],"category_scores_gemma":[0.0006786146,0.00023758566,0.00087924796,0.00029490088,0.00047480993,0.00051358895,0.000213239,0.0013087802,0.00046556132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84668964,0.00999412,0.0025724082,0.0017265622,0.0026304831,0.00008476347,0.00011810675,0.0013169976,0.015918516,0.0004290214,0.003894688,0.11462475],"study_design_scores_gemma":[0.8028005,0.17323437,0.013543996,0.00012713046,0.002185375,0.00021482573,0.0001258471,0.001062651,0.0027333421,0.00035070645,0.0035847188,0.000036657806],"about_ca_topic_score_codex":0.001191873,"about_ca_topic_score_gemma":0.0037523946,"teacher_disagreement_score":0.0025118315,"about_ca_system_score_codex":0.0005408481,"about_ca_system_score_gemma":0.0006482577,"threshold_uncertainty_score":0.008402884},"labels":[],"label_agreement":null},{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","score_opus":0.020862588265296064,"score_gpt":0.3186337084991464,"score_spread":0.29777112023385033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99297684,0.0019778884,0.00035820412,0.00018159465,0.000057604942,0.0008427328,0.0018205068,0.00006974029,0.0017147268],"genre_scores_gemma":[0.97410685,0.0021521673,0.0019504394,0.000900907,0.00014352494,0.0016449749,0.015140605,0.00004659822,0.0039138934],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998254,0.00006601544,0.0000069000835,0.000035804616,0.000022771741,0.000043077427],"domain_scores_gemma":[0.9998385,0.000014665091,0.000027487871,0.000020604395,0.000015987116,0.00008278759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097584823,0.0010250654,0.0010565731,0.0003520348,0.00024084578,0.00074341416,0.00045630243,0.00057288335,0.0021267708],"category_scores_gemma":[0.00031501858,0.00024312596,0.0009053408,0.0002326551,0.00036399672,0.0002924,0.00041129094,0.0011093128,0.0005873011],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5511711,0.030005492,0.043880038,0.0017957764,0.004031892,0.00085564324,0.0005069857,0.0043941047,0.11080159,0.0007658724,0.012131061,0.23966041],"study_design_scores_gemma":[0.38341254,0.41899097,0.13944364,0.000200786,0.0026461412,0.0024195577,0.00028437548,0.0031351505,0.02176462,0.00071502867,0.026916314,0.00007092342],"about_ca_topic_score_codex":0.0010075762,"about_ca_topic_score_gemma":0.0030904557,"teacher_disagreement_score":0.0021267708,"about_ca_system_score_codex":0.0006656376,"about_ca_system_score_gemma":0.00094040926,"threshold_uncertainty_score":0.0071148276},"labels":[],"label_agreement":null},{"id":"W4417530897","doi":"10.1016/j.esmorc.2025.100090","title":"CIRCULATING TUMOR DNA IN PATIENTS WITH INTERMEDIATE RISK RHABDOMYOSARCOMA ON ARST1431: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"School of Medicine, Duke University; Università degli Studi di Padova; Centre Léon Bérard; Ohio State University; Institut Gustave-Roussy; Nationwide Children's Hospital","keywords":"Circulating tumor DNA; Rhabdomyosarcoma; Mutation; Retrospective cohort study; Disease; Circulating tumor cell; Cancer","score_opus":0.003196162349068001,"score_gpt":0.21687995049723713,"score_spread":0.21368378814816913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970836,0.00046852464,0.00025286485,0.00022946295,0.000022209737,0.00001316894,0.00040445742,0.000019951252,0.001505686],"genre_scores_gemma":[0.99912876,0.00014420101,0.00013885541,0.000094543364,0.00003114782,0.000004627424,0.00023823003,0.0000068128898,0.0002127094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976724,0.000023458817,0.000019109732,0.00007020374,0.000057837802,0.00006222554],"domain_scores_gemma":[0.9993259,0.00023342157,0.00014833514,0.0000348455,0.00006590736,0.00019173032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019307726,0.00040554925,0.0003275746,0.0007868112,0.000461513,0.0005179911,0.00036809084,0.0006383382,0.0016605201],"category_scores_gemma":[0.0011688988,0.00026757593,0.0002041062,0.0005340114,0.00044330634,0.00029301754,0.00024424796,0.00061426964,0.0002331743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003037581,0.000055266202,0.9351748,0.000027699021,0.00003842076,0.049797017,0.0003612897,0.00018166892,0.007007659,0.00014825024,0.0012926653,0.005611484],"study_design_scores_gemma":[0.00005746737,0.00032558726,0.8504249,0.000026071646,0.0001280106,0.14118744,0.00077619066,0.0006318744,0.0035079757,0.00019966,0.0027001002,0.00003479554],"about_ca_topic_score_codex":0.0054681646,"about_ca_topic_score_gemma":0.0033300458,"teacher_disagreement_score":0.0054681646,"about_ca_system_score_codex":0.0004231064,"about_ca_system_score_gemma":0.0004003633,"threshold_uncertainty_score":0.010872662},"labels":[],"label_agreement":null},{"id":"W4417530898","doi":"10.1016/j.esmorc.2025.100059","title":"DISSECTING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC TARGETS FROM SINGLE-NUCLEI RNA-SEQ OF CIC::DUX4 ROUND CELL SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Sarcoma; Cell; Tumor cells; Clear-cell sarcoma; Chemotherapy; Cell culture","score_opus":0.023830504558283866,"score_gpt":0.2642154732002451,"score_spread":0.2403849686419612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9183935,0.0024131376,0.06279561,0.00036755108,0.00017099365,0.00010646459,0.0069016106,0.0007246538,0.008126475],"genre_scores_gemma":[0.9620584,0.0010623599,0.025672864,0.00042422587,0.000028157534,0.0001746617,0.0044382084,0.0004212823,0.00571976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983764,0.000009770716,0.000006779392,0.000065889755,0.000054020576,0.000025922176],"domain_scores_gemma":[0.99987805,0.000043263983,0.000015961974,0.000010968358,0.000034673594,0.000017034314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031508613,0.00017545155,0.00028335743,0.0002642487,0.00035875782,0.00061420584,0.00018085729,0.00034755084,0.0018423593],"category_scores_gemma":[0.00034429177,0.00021891584,0.00018805025,0.00019414687,0.00025564642,0.00027655653,0.0002413529,0.0005433402,0.00056827196],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000705592,0.000009570274,0.0017555396,0.0000892871,0.000014021584,0.000036320595,0.00009112588,0.00079395314,0.9901571,0.00045888932,0.0005040675,0.006019602],"study_design_scores_gemma":[0.000024876948,0.000112840054,0.04054774,0.00003493732,0.00007595834,0.0002882802,0.00038684873,0.027510546,0.9093071,0.00082244474,0.020855524,0.000032951546],"about_ca_topic_score_codex":0.0021486343,"about_ca_topic_score_gemma":0.0068380437,"teacher_disagreement_score":0.0021486343,"about_ca_system_score_codex":0.00036749057,"about_ca_system_score_gemma":0.00031683297,"threshold_uncertainty_score":0.006163299},"labels":[],"label_agreement":null},{"id":"W4417530903","doi":"10.1016/j.esmorc.2025.100079","title":"PREOPERATIVE RADIOTHERAPY AND POSTOPERATIVE COMPLICATIONS AMONG PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA: A POST HOC ANALYSIS OF THE EORTC-62092 (STRASS) PHASE 3 RANDOMIZED CLINICAL TRIAL","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Randomized controlled trial; Post-hoc analysis; Clinical trial; Radiation therapy; Intention-to-treat analysis; Post hoc","score_opus":0.01606725772035284,"score_gpt":0.33226002791445214,"score_spread":0.3161927701940993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996626,0.001751407,0.0001885657,0.00020660022,0.000075763564,0.00029516575,0.00042432908,0.00001585447,0.00041628833],"genre_scores_gemma":[0.9974619,0.00047390454,0.0003038423,0.00024908248,0.00012752267,0.0003605647,0.00056757475,0.0000079149495,0.00044767896],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981426,0.0013729236,0.000106358966,0.00018734937,0.000090372836,0.00010032366],"domain_scores_gemma":[0.9978168,0.0009007127,0.00069886754,0.00018324098,0.000081250284,0.00031914542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004025821,0.0007476542,0.0013634014,0.00022367598,0.00022484707,0.0007334956,0.00049775315,0.00078392384,0.0026385002],"category_scores_gemma":[0.0032838178,0.00033168978,0.0024547167,0.00031840455,0.00048419577,0.0005731898,0.00037929055,0.0012197468,0.0002962202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94119126,0.0027246906,0.035207238,0.00033889952,0.0057186903,0.0000518432,0.00004594621,0.0006445029,0.0013034734,0.00007051939,0.00066961476,0.0120333005],"study_design_scores_gemma":[0.67561036,0.15161699,0.1565724,0.00010188013,0.009801525,0.00015808723,0.0000889502,0.0031520412,0.0009787424,0.00038390054,0.0014840232,0.00005110894],"about_ca_topic_score_codex":0.0005674752,"about_ca_topic_score_gemma":0.0014764837,"teacher_disagreement_score":0.004025821,"about_ca_system_score_codex":0.00042242734,"about_ca_system_score_gemma":0.00083030213,"threshold_uncertainty_score":0.021290839},"labels":[],"label_agreement":null},{"id":"W4417530910","doi":"10.1016/j.esmorc.2025.100062","title":"MINNELIDE IS A NOVEL THERAPEUTIC INHIBITOR OF CIC::DUX4 SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Magnesium in Health and Disease","field":"Nursing","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Sarcoma; Cancer; Immunotherapy; Soft tissue sarcoma; Drug","score_opus":0.019101758309346035,"score_gpt":0.3049709616630899,"score_spread":0.2858692033537439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417530910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8456461,0.107577465,0.0043748594,0.0037799021,0.0011805042,0.0005417706,0.0019749657,0.00082478096,0.034099642],"genre_scores_gemma":[0.95832396,0.025327161,0.0034764837,0.0008558978,0.00018621562,0.00017206272,0.0015416404,0.000054798536,0.010061755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999285,0.000013475968,0.000007762177,0.000012670346,0.000014152451,0.000023446204],"domain_scores_gemma":[0.99996233,0.0000057700845,0.000008371269,0.0000037867562,0.0000044788744,0.000015295669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012584805,0.00031651507,0.00061066594,0.00028064087,0.0002541816,0.00039431822,0.00046265408,0.0005289561,0.004821803],"category_scores_gemma":[0.00017023724,0.000106895415,0.00033403424,0.00024605074,0.0002027272,0.00030580166,0.00036756258,0.0010055279,0.00082009577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012932967,0.0018579607,0.00250943,0.0023190314,0.00042117405,0.0017220237,0.00021968727,0.0010387356,0.67387766,0.004265992,0.01733465,0.28150076],"study_design_scores_gemma":[0.009222322,0.01857202,0.018376399,0.00036631824,0.00049119646,0.009280284,0.00037219908,0.0023113177,0.5795434,0.0017351911,0.3596319,0.000097385026],"about_ca_topic_score_codex":0.0007061552,"about_ca_topic_score_gemma":0.0018037956,"teacher_disagreement_score":0.004821803,"about_ca_system_score_codex":0.00045397435,"about_ca_system_score_gemma":0.00041978693,"threshold_uncertainty_score":0.016130567},"labels":[],"label_agreement":null},{"id":"W7116631298","doi":"10.1016/j.esmorc.2025.100103","title":"PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Fibrosis; Soft tissue sarcoma; Soft tissue; Thigh; Sarcoma; Subcutaneous tissue; Vortex","score_opus":0.04187978627994771,"score_gpt":0.3401438212695845,"score_spread":0.2982640349896368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116631298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384863,0.007620661,0.03203638,0.0014738826,0.0001775048,0.00046117645,0.005177904,0.0005470895,0.014019101],"genre_scores_gemma":[0.9820479,0.0008538825,0.011139681,0.00027362036,0.000066110755,0.00021720029,0.0031427818,0.00027579584,0.0019830836],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9991885,0.00056521076,0.00002678227,0.00006058239,0.0001213788,0.000037485213],"domain_scores_gemma":[0.9970124,0.0022299772,0.00033764998,0.00013249594,0.00012561944,0.00016188229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029277285,0.0007270177,0.0007778247,0.00037944713,0.00012034021,0.0009364969,0.0006221872,0.0004995393,0.0035539325],"category_scores_gemma":[0.0060582883,0.00025730432,0.0009508451,0.00028920802,0.00033907333,0.0005116835,0.00050208037,0.0009588901,0.0005973894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0581124,0.0018367395,0.08959938,0.001441854,0.0017637492,0.00044597962,0.0002505476,0.62384087,0.050513685,0.0055385334,0.011790143,0.15486614],"study_design_scores_gemma":[0.009073995,0.026017364,0.09105819,0.00038464292,0.0022908784,0.0009199804,0.00037119913,0.8067424,0.037565656,0.007215303,0.01812305,0.000237379],"about_ca_topic_score_codex":0.0016205767,"about_ca_topic_score_gemma":0.002847726,"teacher_disagreement_score":0.0035539325,"about_ca_system_score_codex":0.0004739139,"about_ca_system_score_gemma":0.00063576724,"threshold_uncertainty_score":0.015483558},"labels":[],"label_agreement":null},{"id":"W7116631937","doi":"10.1016/j.esmorc.2025.100070","title":"EXPLORING ACTIONABLE THERAPEUTIC TARGETS ASSOCIATED WITH SMARCB1 DEFICIENCY IN EPITHELIOID SARCOMA","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Epithelioid sarcoma; Sarcoma; SMARCB1; Disease; Mutation; Soft tissue sarcoma","score_opus":0.03014984236719089,"score_gpt":0.2573838991908916,"score_spread":0.2272340568237007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116631937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70336545,0.2555948,0.0144454595,0.0046812184,0.0004354313,0.00029208045,0.0010445135,0.00033138567,0.019809714],"genre_scores_gemma":[0.9398694,0.051451303,0.0034100928,0.00067108765,0.00008956218,0.00015094742,0.0006549539,0.00002762396,0.0036750254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998715,0.00003152199,0.000008590752,0.000019903588,0.000028760942,0.00003970619],"domain_scores_gemma":[0.9999248,0.000020155956,0.000020386742,0.000007327233,0.000011404363,0.000015888949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045081272,0.00031468627,0.00045700173,0.000357116,0.00018196451,0.0007462089,0.00036815982,0.0004681221,0.0024610278],"category_scores_gemma":[0.00023808726,0.00015471365,0.0003032112,0.00029473225,0.0003127136,0.0003789407,0.00030881524,0.0008614332,0.0004880976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001751628,0.0003895983,0.0033767752,0.001264656,0.00012829498,0.0009052555,0.00013516087,0.0020399897,0.84682256,0.0075674416,0.0032429176,0.13237575],"study_design_scores_gemma":[0.0009539648,0.006387236,0.017801194,0.0005492888,0.00052542397,0.0046670935,0.00059351564,0.0059941704,0.7634373,0.0067021046,0.19232467,0.0000642022],"about_ca_topic_score_codex":0.0002876927,"about_ca_topic_score_gemma":0.0008890514,"teacher_disagreement_score":0.0024610278,"about_ca_system_score_codex":0.00049054704,"about_ca_system_score_gemma":0.00040075643,"threshold_uncertainty_score":0.008232892},"labels":[],"label_agreement":null}]}